Pasireotide + Cabergoline + Pasireotide LAR
ApprovedCompleted 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Cushing's Disease
Conditions
Cushing's Disease, Acromegaly, Neuroendocrine Tumors, Pituitary Tumors, Ectopic ACTH Secreting (EAS) Tumors, Dumping Syndrome, Prostate Cancer, Melanoma Negative for bRAF, Melanoma Negative for nRAS
Trial Timeline
Jun 10, 2013 → Jul 25, 2023
NCT ID
NCT01794793About Pasireotide + Cabergoline + Pasireotide LAR
Pasireotide + Cabergoline + Pasireotide LAR is a approved stage product being developed by Recordati for Cushing's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01794793. Target conditions include Cushing's Disease, Acromegaly, Neuroendocrine Tumors.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01794793 | Approved | Completed |
Competing Products
18 competing products in Cushing's Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD4017 and prednisolone + Placebo Oral Tablet and prednisolone | AstraZeneca | Phase 2 | 52 |
| pasireotide LAR + SOM230 LAR 30 mg + SOM230 LAR 10 mg | Novartis | Phase 3 | 77 |
| Pasireotide sub-cutaneous | Novartis | Phase 3 | 77 |
| osilodrostat + osilodrostat Placebo | Novartis | Phase 3 | 77 |
| Osilodrostat | Novartis | Phase 2 | 52 |
| Pasireotide | Novartis | Phase 3 | 77 |
| Pasireotide s.c. + Sitagliptin + Liraglutide + Insulin + Pasireotide LAR + Metformin | Novartis | Approved | 85 |
| SOM230 s.c. | Novartis | Phase 2 | 52 |
| Lu AG13909 | Lundbeck | Phase 2 | 49 |
| Osilodrostat | Recordati | Pre-clinical | 20 |
| osilodrostat | Recordati | Phase 2 | 49 |
| Osilodrostat | Recordati | Pre-clinical | 20 |
| mifepristone | Corcept Therapeutics | Phase 3 | 72 |
| CORT125134 | Corcept Therapeutics | Phase 2 | 47 |
| Cushing's syndrome confirmation | Corcept Therapeutics | Pre-clinical | 18 |
| Mifepristone | Corcept Therapeutics | Phase 3 | 72 |
| mifepristone | Corcept Therapeutics | Phase 3 | 72 |
| mifepristone | Corcept Therapeutics | Phase 3 | 72 |